47 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
infection ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
in HIV-AIDS Preventing ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
BEE Syndromes - Non-inflammatory Causes

Immune-mediated conditions affecting the Brain, Eye, and Ear

Visual or auditory symptoms in
Non-inflammatory Causes ... diagnosis and treatment ... Non-inflammatory causes ... pachymeningitis • HIV ... #neurology #noninflammatory
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
in HIV-AIDS Preventing ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Causes of Fatigue - Differential Diagnosis Algorithm
Endocrine
 • Hypo/Hyperthyroidism
 • Diabetes
 • Pituitary Insufficiency
 • Adrenal
• Malignancy Infectious ... Hepatitis • HIV ... Pulmonary Disease Neurologic ... Myasthenia Gravis Pharmacologic ... Chronic Fatigue Syndrome
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
in HIV-AIDS Treating ... General Management ... IDSA #Prevention #Treatment ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
• Continue treatment ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
with positive serology ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... Leishmaniasis #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... for effective treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology